Originally published by our sister publication Specialty Pharmacy Continuum
By SPC Staff
The FDA approved dupilumab (Dupixent, Sanofi/Regeneron) to treat eosinophilic esophagitis (EoE) in children ages 1 year and older weighing at least 15 kg. The agency previously approved dupilumab in 2022, for patients with EoE 12 years and older, weighing at least 40 kg. 
Dupilumab is a monoclonal antibody that inhibits interleukin-4 and interleukin-13 signaling and is not an immunosuppressant. The new